<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DICLOFENAC- diclofenac sodium solution/ drops </strong><br>Lake Erie Medical DBA Quality Care Products LLC<br></p></div>
<h1>DICLOFENAC SODIUM<br>OPHTHALMIC SOLUTION, 0.1%
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First">Rx Only
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION:
</h1>
<p class="First">Diclofenac Sodium Ophthalmic Solution, 0.1% is a sterile, topical, nonsteroidal anti-inflammatory product for ophthalmic use. Diclofenac Sodium is designated chemically as 2-[(2,6-dichlorophenyl)amino] benzeneacetic acid, monosodium salt, with an empirical formula of C<span class="Sub">14</span>H<span class="Sub">10</span>Cl<span class="Sub">2</span>NO<span class="Sub">2</span>Na. The structural formula of Diclofenac Sodium is:</p>
<div class="Figure"><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=980b3b80-44cb-44b5-89cc-d451a3b20ae3&amp;name=dic03-0000-01.jpg"></div>
<p>Diclofenac Sodium Ophthalmic Solution, 0.1% is available as a sterile solution which contains diclofenac sodium 0.1% (1 mg/mL).</p>
<p><span class="Bold">Inactive Ingredients:</span> boric acid, edetate disodium (1 mg/mL), polyoxyl 35 castor oil, water for injection, sorbic acid (2 mg/mL), tromethamine.</p>
<p>Diclofenac Sodium is a faintly yellow-white to light-beige, slightly hygroscopic crystalline powder. It is freely soluble in methanol, sparingly soluble in water, very slightly soluble in acetonitrile, and insoluble in chloroform and in 0.1N hydrochloric acid. Its molecular weight is 318.14. Diclofenac Sodium Ophthalmic Solution is an iso-osmotic solution with an <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of about 300 mOsmol/1000 g, buffered at approximately pH 7.2. Diclofenac Sodium Ophthalmic Solution has a <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> characteristic odor of castor oil.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY:
</h1>
<div class="Section" data-sectionCode="43681-6">
<a name="s4"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacodynamics
</h2>
<p class="First">Diclofenac Sodium is one of a series of phenylacetic acids that has demonstrated anti-inflammatory and analgesic properties in pharmacological studies. It is thought to inhibit the enzyme cyclooxygenase, which is essential in the biosynthesis of prostaglandins.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-3.2"></a><p></p>
<h2>Animal Studies
</h2>
<p class="First">Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, and <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>.
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s6"></a><a name="section-3.3"></a><p></p>
<h2>Pharmacokinetics
</h2>
<p class="First">Results from a bioavailability study established that plasma levels of diclofenac following ocular instillation of two drops of Diclofenac Sodium Ophthalmic Solution to each eye were below the limit of quantification (10 ng/mL) over a 4-hour period. This study suggests that limited, if any, systemic absorption occurs with Diclofenac Sodium Ophthalmic Solution.
</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s7"></a><a name="section-3.4"></a><p></p>
<h2>Clinical Trials:
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-3.4.1"></a><p></p>
<h3>Postoperative Anti-Inflammatory Effects:
</h3>
<p class="First">In two double-masked, controlled, efficacy studies of postoperative <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, a total of 206 <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> patients were treated with Diclofenac Sodium Ophthalmic Solution and 103 patients were treated with vehicle placebo. Diclofenac Sodium Ophthalmic Solution was favored over vehicle placebo over a 2-week period for the clinical assessments of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> as measured by <span class="product-label-link" type="condition" conceptid="4081011" conceptname="Anterior chamber cells">anterior chamber cells</span> and flare.
</p>
<p>In double-masked, controlled studies of corneal refractive surgery (radial keratotomy (RK) and laser photorefractive keratectomy (PRK)) patients were treated with Diclofenac Sodium Ophthalmic Solution and/or vehicle placebo. The efficacy of Diclofenac Sodium Ophthalmic Solution given before and shortly after surgery was favored over vehicle placebo during the 6-hour period following surgery for the clinical assessments of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>. Patients were permitted to use a hydrogel soft contact lens with Diclofenac Sodium Ophthalmic Solution for up to three days after PRK.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s9"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE:
</h1>
<p class="First">Diclofenac Sodium Ophthalmic Solution, 0.1% is indicated for the treatment of postoperative <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> in patients who have undergone <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> extraction and for the temporary relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span> in patients undergoing corneal refractive surgery.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s10"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS:
</h1>
<p class="First">Diclofenac Sodium Ophthalmic Solution, 0.1% is contraindicated in patients who are hypersensitive to any component of the medication.
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s11"></a><a name="section-6"></a><p></p>
<h1>WARNINGS:
</h1>
<p class="First">The refractive stability of patients undergoing corneal refractive procedures and treated with Diclofenac Sodium Ophthalmic Solution has not been established. Patients should be monitored for a year following use in this setting.
</p>
<p>With some nonsteroidal anti-inflammatory drugs, there exists the potential for increased <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> due to interference with thrombocyte aggregation. There have been reports that ocularly applied nonsteroidal anti-inflammatory drugs can cause increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> of ocular tissues (including <span class="product-label-link" type="condition" conceptid="432904" conceptname="Hyphema">hyphemas</span>) in conjunction with ocular surgery.
</p>
<p>There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory agents. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s12"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS:
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s13"></a><a name="section-7.1"></a><p></p>
<h2>General
</h2>
<p class="First">All topical nonsteroidal anti-inflammatory drugs (NSAIDs) may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.
</p>
<p>Use of topical NSAIDs may result in <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>. In some susceptible patients continued use of topical NSAIDs may result in epithelial breakdown, <span class="product-label-link" type="condition" conceptid="4307537" conceptname="Corneal thinning">corneal thinning</span>, <span class="product-label-link" type="condition" conceptid="4232690" conceptname="Infiltrate of cornea">corneal infiltrates</span>, <span class="product-label-link" type="condition" conceptid="4179918" conceptname="Corneal erosion">corneal erosion</span>, <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulceration</span>, and <span class="product-label-link" type="condition" conceptid="4326414" conceptname="Perforation of cornea">corneal perforation</span>. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs and should be closely monitored for corneal health.
</p>
<p>Postmarketing experience with topical NSAIDs suggest that patients experiencing complicated ocular surgeries, corneal denervation, corneal epithelial defects, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, ocular surface disease (e.g., <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye syndrome</span>), <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, or repeat ocular surgeries within a short period-of-time may be at increased risk for corneal adverse events, which may become sight threatening. Topical NSAIDs should be used with caution in these patients.
</p>
<p>Postmarketing experience with topical NSAIDs also suggests that use more than 24 hours prior to surgery or use beyond 14 days post surgery may increase patient risk for occurrence and severity of corneal adverse events.
</p>
<p>It is recommended that Diclofenac Sodium Ophthalmic Solution, like other NSAIDs, be used with caution in patients with known <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> tendencies or who are receiving other medications which may prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>.
</p>
<p>Results from clinical studies indicate that Diclofenac Sodium Ophthalmic Solution has no significant effect upon ocular pressure. However, elevation in intraocular pressure may occur following <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s14"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients
</h2>
<p class="First">Except of the use of a bandage hydrogel soft contact lens during the first 3 days following refractive surgery, Diclofenac Sodium Ophthalmic Solution should not be used by patients currently wearing soft contact lenses due to adverse events that have occurred in other circumstances.
</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s15"></a><a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Long-term carcinogenicity studies in rats given Diclofenac Sodium Ophthalmic Solution in oral doses up to 2 mg/kg/day (approximately 500 times the human topical ophthalmic dose) revealed no significant increases in tumor incidence. A 2-year carcinogenicity study conducted in mice employing oral Diclofenac Sodium Ophthalmic Solution up to 2 mg/kg/day did not reveal any oncogenic potential. Diclofenac Sodium Ophthalmic Solution did not show mutagenic potential in various mutagenicity studies including the Ames test. Diclofenac Sodium Ophthalmic Solution administered to male and female rats at 4 mg/kg/day (approximately 1000 times the human topical ophthalmic dose) did not effect fertility.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s16"></a><a name="section-7.4"></a><p></p>
<h2>Geriatric Use:
</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger adult patients.
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s17"></a><a name="section-7.5"></a><p></p>
<h2>PREGNANCY:
</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s18"></a><a name="section-7.5.1"></a><p></p>
<h3>Teratogenic Effects
</h3>
<p class="First">Pregnancy Category C. Reproduction studies performed in mice at oral doses up to 5,000 times (20 mg/kg/day) and in rats and rabbits at oral doses up to 2,500 times (10 mg/kg/day) the human topical dose have revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> due to Diclofenac Sodium Ophthalmic Solution despite the induction of maternal toxicity and fetal toxicity. In rats, maternally toxic doses were associated with dystocia, prolonged gestation, reduced fetal weights and growth, and reduced fetal survival. Diclofenac Sodium Ophthalmic Solution has been shown to cross the placental barrier in mice and rats.
</p>
<p>There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="s19"></a><a name="section-7.6"></a><p></p>
<h2>Non-teratogenic Effects
</h2>
<p class="First">Because of the known effects of prostaglandin biosynthesis-inhibiting drugs on the fetal cardiovascular system (closure of ductus arteriosus), the use of Diclofenac Sodium Ophthalmic Solution during late pregnancy should be avoided.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s20"></a><a name="section-7.7"></a><p></p>
<h2>Pediatric Use
</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s21"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS:
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-8.1"></a><p></p>
<p class="First"><span class="Bold">Clinical Practice:</span> The following events have been identified during postmarketing use of topical diclofenac sodium ophthalmic solution, 0.1% in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The events which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to topical diclofenac sodium ophthalmic Solution, 0.1%, or a combination of these factors, include <span class="product-label-link" type="condition" conceptid="4179918" conceptname="Corneal erosion">corneal erosion</span>, <span class="product-label-link" type="condition" conceptid="4232690" conceptname="Infiltrate of cornea">corneal infiltrates</span>, <span class="product-label-link" type="condition" conceptid="4326414" conceptname="Perforation of cornea">corneal perforation</span>, <span class="product-label-link" type="condition" conceptid="4307537" conceptname="Corneal thinning">corneal thinning</span>, <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulceration</span>, epithelial breakdown, and <span class="product-label-link" type="condition" conceptid="375265" conceptname="Punctate keratitis">superficial punctate keratitis</span> (see <span class="Bold"><a href="#s13">Precautions, General</a>).</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-8.2"></a><p></p>
<p class="First"><span class="Bold">Ocular:</span> Transient burning and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> were reported in approximately 15% of patients across studies with the use of Diclofenac Sodium Ophthalmic Solution. In <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery studies, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> was reported in up to 28% of patients receiving Diclofenac Sodium Ophthalmic Solution, although in many of these cases <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> was initially noted prior to the initiation of treatment. Elevated intraocular pressure following <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery was reported in approximately 15% of patients undergoing <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery. <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">Lacrimation</span> complaints were reported in approximately 30% of case studies undergoing incisional refractive surgery.
</p>
<p>The following adverse reactions were reported in approximately 5% or less of the patients: <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, acute elevated IOP, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="4080669" conceptname="Keratic precipitates">corneal deposits</span>, <span class="product-label-link" type="condition" conceptid="377875" conceptname="Idiopathic corneal edema">corneal edema</span>, <span class="product-label-link" type="condition" conceptid="378752" conceptname="Corneal opacity">corneal opacity</span>, <span class="product-label-link" type="condition" conceptid="4270897" conceptname="Corneal lesion">corneal lesions</span>, discharge, eyelid <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, injection, <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>, irritation, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span> disorder and ocular <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-8.3"></a><p></p>
<p class="First"><span class="Bold">Systemic:</span> The following adverse reactions were reported in 3% or less of the patients: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s25"></a><a name="section-9"></a><p></p>
<h1>Overdosage:
</h1>
<p class="First">Overdosage will not ordinarily cause acute problems. If Diclofenac Sodium Ophthalmic Solution is accidentally ingested, fluids should be taken to dilute the medication.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s26"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION:
</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataract</span> Surgery: One drop of Diclofenac Sodium Ophthalmic Solution, 0.1% should be applied to the affected eye, 4 times daily beginning 24 hours after <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery and continuing throughout the first 2 weeks of the post operative period.
</p>
<p>Corneal Refractive Surgery: One or two drops of Diclofenac Sodium Ophthalmic Solution, 0.1% should be applied to the operative eye within the hour prior to corneal refractive surgery. Within 15 minutes after surgery, one or two drops should be applied to the operative eye and continued 4 times daily for up to 3 days.
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s27"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED:
</h1>
<p class="First">Diclofenac Sodium Ophthalmic Solution, 0.1% (1 mg/mL) Solution is supplied in a low density polyethylene (LDPE) white bottle with a LDPE Dropper Tip and Polypropylene grey closure. The 2.5 mL fill is supplied in a 10 mL size bottle. The 5.0 mL fill is also supplied in a 10.0 mL size bottle.
</p>
<p>Bottles of 2.5 mL                 NDC 17478-892-25
</p>
<p>Bottles of 5 mL                       NDC 17478-892-10
</p>
<div class="Section" data-sectionCode="44425-7">
<a name="s28"></a><a name="section-11.1"></a><p></p>
<p class="First"><span class="Bold">STORAGE:</span> Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
</p>
<p><span class="Bold">Protect from freezing and light.</span></p>
<p>Dispense in original, unopened container only.
</p>
<p><span class="Bold">Akorn<br></span>Manufactured by: Akorn Inc.<br>Lake Forest, IL 60045
</p>
<p>DC00N                                                                                                                                               Rev. 12/12
</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="L6435e549-3256-4b3f-b3fa-8c947776ddc4"></a><a name="section-12"></a><p></p>
<h1>Image of Label</h1>
<p class="First"><img alt="Image of Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=980b3b80-44cb-44b5-89cc-d451a3b20ae3&amp;name=scan0070.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DICLOFENAC 		
					</strong><br><span class="contentTableReg">diclofenac sodium solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:35356-554(NDC:17478-892)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DICLOFENAC SODIUM</strong> (DICLOFENAC) </td>
<td class="formItem">DICLOFENAC SODIUM</td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYOXYL 35 CASTOR OIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SORBIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TROMETHAMINE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:35356-554-05</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2.5 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077845</td>
<td class="formItem">05/01/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Lake Erie Medical DBA Quality Care Products LLC
							(831276758)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Lake Erie Medical DBA Quality Care Products LLC</td>
<td class="formItem"></td>
<td class="formItem">831276758</td>
<td class="formItem">relabel(35356-554)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b304a48c-e7e2-43f5-96b8-72aac96f5e78</div>
<div>Set id: 980b3b80-44cb-44b5-89cc-d451a3b20ae3</div>
<div>Version: 1</div>
<div>Effective Time: 20150403</div>
</div>
</div> <div class="DistributorName">Lake Erie Medical DBA Quality Care Products LLC</div></p>
</body></html>
